We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
(+29%)
Cap. Flow
+$32.2M
Cap. Flow
% of AUM
1.94%
Top 10 Holdings %
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
2.8
quarters
Top 20 Avg Time Held Equity + Options
3
quarters
Avg Time Held Equity only
2.2
quarters
Top 10 Avg Time Held Equity only
2.9
quarters
Top 20 Avg Time Held Equity only
3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$23.8M |
| 2 |
Viatris
VTRS
|
+$14.8M |
| 3 |
Eagle Pharmaceuticals, Inc.
EGRX
|
+$14.4M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$12.4M |
| 5 |
NEVRO CORP.
NVRO
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$19.4M |
| 2 |
bluebird bio
BLUE
|
+$16.3M |
| 3 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$12.1M |
| 4 |
uniQure
QURE
|
+$11.1M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.96% |
| 2 | Miscellaneous | 17.3% |
| 3 | Consumer Staples | 0.52% |
| 4 | Financials | 0.09% |
| 5 | Technology | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PMC
151
DELISTED
PharMerica Corporation
PMC
| $226K | 0.01% |
+6,800
| New | +$209K |
2015 Q2
0 quarters
|
|
152
Icon
ICLR
$12.7B
| $225K | 0.01% |
3,348
+450
| +16% | +$30.4K |
2015 Q1
1 quarter
|
|
153
Enanta Pharmaceuticals
ENTA
$336M
| $223K | 0.01% |
+4,956
| New | +$193K |
2015 Q2
0 quarters
|
|
154
Cardinal Health
CAH
$55.5B
| $215K | 0.01% |
2,574
| – | – |
2015 Q1
1 quarter
|
|
155
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $215K | 0.01% |
1,493
-32,081
| -96% | -$4.58M |
2013 Q4
6 quarters
|
|
156
DELISTED
SYNERGETICS USA, INC.
SURG
| $208K | 0.01% |
44,266
+22,480
| +103% | +$109K |
2015 Q1
1 quarter
|
|
157
UnitedHealth
UNH
$339B
| $206K | 0.01% |
+1,685
| New | +$199K |
2015 Q2
0 quarters
|
|
158
Molina Healthcare
MOH
$10.9B
| $203K | 0.01% |
+2,888
| New | +$193K |
2015 Q2
0 quarters
|
|
|
MGLN
159
DELISTED
Magellan Health Services, Inc.
MGLN
| $203K | 0.01% |
2,900
| – | – |
2015 Q1
1 quarter
|
|
|
DVCR
160
DELISTED
Diversicare Healthcare Services Inc
DVCR
| $198K | 0.01% |
+15,337
| New | +$225K |
2015 Q2
0 quarters
|
|
|
EVFM
161
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $180K | 0.01% |
+222
| New | +$142K |
2015 Q2
0 quarters
|
|
162
Ascendis Pharma A/S
ASND
$14.7B
| $176K | 0.01% |
10,000
| – | – |
2015 Q1
1 quarter
|
|
|
XIV
163
DELISTED
VelocityShares Daily Inverse VIX Short Term ETN
XIV
| $162K | 0.01% |
+4,000
| New | +$171K |
2015 Q2
0 quarters
|
|
164
Novo Nordisk
NVO
$168B
| $128K | 0.01% |
+4,680
| New | +$132K |
2015 Q2
0 quarters
|
|
|
NSPH
165
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $115K | 0.01% |
+35,379
| New | +$136K |
2015 Q2
0 quarters
|
|
166
DBV Technologies S.A. American Depositary Shares
DBVT
$568M
| $89K | 0.01% |
+300
| New | +$77.5K |
2015 Q2
0 quarters
|
|
167
Myriad Genetics
MYGN
$390M
| $85K | 0.01% |
+2,500
| New | +$85K |
2015 Q2
0 quarters
|
|
168
Capricor Therapeutics
CAPR
$400M
| $20K | ﹤0.01% |
400
| – | – |
2015 Q1
1 quarter
|
|
169
Pacira BioSciences
PCRX
$1.45B
| $4K | ﹤0.01% |
+50
| New | +$3.94K |
2015 Q2
0 quarters
|
|
170
Agenus
AGEN
$314M
| – | – |
-9,228
| Closed | -$929K | – |
|
171
Biogen
BIIB
$33.8B
| – | – |
-18,200
| Closed | -$7.68M | – |
|
172
Brookdale Senior Living
BKD
$2.42B
| – | – |
-5,000
| Closed | -$189K | – |
|
|
173
DELISTED
bluebird bio
BLUE
| – | – |
-10,422
| Closed | -$16.3M | – |
|
174
Cytokinetics
CYTK
$8.57B
| – | – |
-30,227
| Closed | -$205K | – |
|
175
DELISTED
DURECT Corp
DRRX
| – | – |
-90,706
| Closed | -$1.73M | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors's Q2 2015 filing shows 55 new, 41 increased, 36 reduced and 38 closed positions. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M. The largest sale was Neurocrine Biosciences, an estimated $19.4M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
- Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
- Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
- Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
- Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
- Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.
Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.